Axios Biosciences is revolutionizing oncology drug discovery by identifying drugs active in the tumor microenvironment where tumors interact with non-malignant tissue and can dramatically affect drug sensitivity. The firm is using unique technologies, including one published in the journal Nature Medicine, to identify promising compounds for primary or metastatic cancers in the bone.
